FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2985072863> ?p ?o ?g. }

• W2985072863 endingPage "176" @default.
• W2985072863 startingPage "176" @default.
• W2985072863 abstract "Introduction Venetoclax (VEN), a potent BCL2 inhibitor, demonstrated favorable outcomes combined with hypomethylating agents and low dose cytarabine (AraC) in elderly patients (pts) newly diagnosed (ND) with acute myeloid leukemia (AML). In order to improve both remission rates and survival in fit AML pts, we evaluated the combination of VEN with FLAG-IDA regimen in fit pts with ND or relapsed/refractory (R/R) AML. Objectives This phase (Ph) Ib/II single center clinical trial has dual primary objectives: (1) Safety and tolerability of the combination for pts with R/R AML (Ph Ib), and (2) Overall response rate (ORR) by modified IWG AML criteria in pts ND or R/R AML (Ph II). Secondary analyses include duration of response (DOR) and overall survival (OS). Methods Eligibility includes medically fit, ND or R/R AML pts of any age with adequate organ function, PS ≤ 2, and WBC &lt; 25x109/L. Only R/R AML pts were eligible for Ph Ib dose escalation. Pts receive FLAG-IDA induction/consolidation (ind/cons), with VEN orally daily. The original FLAG-IDA ind consisted of fludarabine 30 mg/m2 IV D2-6, AraC 2 g/m2 IV D2-6, idarubicin 6 mg/m2 IV D4-6 (8 mg/m2 IV D4-6 for ND pts), and filgrastim 5 mcg/kg daily D1-7 (or pegfilgrastim 6 mg after day 5 to replace remaining injections). The 3+3 algorithm was applied for dose escalation. The first cohort (dose -1, n=8) received FLAG-IDA with VEN 200 mg on days 1-21 of ind, incorporating a 2-day VEN dose ramp up. After the observation of gram negative bacteremia and/or sepsis in 5 of 6 pts during cycle 1 nadir, an amended dose level -1 ind was designed with reduced AraC 1.5 g/m², with VEN 200 mg on D1-14 and dose level 0 with VEN 400mg on D1-14. After completion of ind/cons, single agent VEN at 400 mg continuously is provided as maintenance for pts not proceeding to alloSCT. The data cutoff was 6.10.2019. Results At data cutoff, 34 pts with a median age of 47 yrs (range, 21-72) have been enrolled: 16 pts in the Ph Ib, and 18 pts in Ph II (11 in ND, and 7 in R/R cohort). 23 pts had R/R AML with a median of 2 (range, 1-4) prior therapies, and 10 (43%) pts had received prior alloSCT. Additional demographics including molecular profile at study enrollment are provided in Table 1. The median number of cycles received is 2 (range, 1-4). VEN 400 mg on D1-14 was considered safe for Ph II dose expansion. Serious adverse events regardless of causality were infections (n=26), bacteremia (n=12), sepsis (n=5), hypotension (n=4) and typhlitis (n=3). No tumor lysis syndrome was identified. 30-day mortality was 0%, 60-day mortality was 0% in ND cohort and 13% in R/R cohort (2 pts died from progression and 1 pt from fungal pneumonia). All enrolled pts were evaluable for response. Of 23 R/R pts, 17 pts (74%) achieved a best response of CR/CRi (12 CR, 5 CRi: 3 CRh + 2 CRp). 12 (52%) pts attained MRD negative status by flow cytometry. 15 pts attained a best response after one cycle, and two attained blast reduction after cycle 1 followed by CR after re-induction. Among responders, 9 pts proceeded to alloSCT, 2 remain on study, 3 pts relapsed, and 3 pts died in CR at 1.7, 3.4 and 4.6 months on treatment. Median time to ANC recovery &gt; 500/ul and platelet recovery &gt; 50K in responders was 27 days (range, 20-90) and 33 days (range, 20-54) respectively. With a median follow-up of 5 months, median DOR is not reached and OS is 7.1 months. Median OS for pts in salvage 1, 2, and ≥ 3 is 9.4, 10, and 4.9 months, respectively. Of 11 ND pts, 10 pts (91%) achieved ORR (9 CR, 1 CRh) and all 10 pts became MRD negative by flow cytometry: 3 pts proceeded to alloSCT, and 7 pts remain on active treatment. Median time to ANC and platelet recovery with induction was 23 days (range, 19-31) and 25 days (range, 18-31) respectively. Both DOR and OS are not estimable. Of interest, responding pts demonstrated higher apoptosis priming, as shown by depolarization in response to Bid, PUMA and Bim peptides by BH3 profiling (Fig 1). Conclusions FLAG-IDA with VEN demonstrates notable activity in both R/R and ND medically fit pts. Improved safety and tolerability without decreasing efficacy was achieved by decreasing AraC to 1.5 g/m2, and administering VEN for 14 days in ind, and 7 days in cons cycles. Neither prolonged cytopenias nor early mortality were observed. Ph II portion for R/R and ND pts is ongoing. Correlative studies with genomic annotation, CyTOF analysis and BH3 profiling are being analyzed, with higher apoptosis priming identified in responding pts. Longer follow-up is necessary to establish long term survival benefit. Table 1 Disclosures Konopleva: Stemline Therapeutics: Consultancy, Honoraria, Research Funding; Kisoji: Consultancy, Honoraria; Reata Pharmaceuticals: Equity Ownership, Patents & Royalties; Calithera: Research Funding; Ablynx: Research Funding; Astra Zeneca: Research Funding; Agios: Research Funding; Forty-Seven: Consultancy, Honoraria; Eli Lilly: Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Cellectis: Research Funding; Amgen: Consultancy, Honoraria; F. Hoffman La-Roche: Consultancy, Honoraria, Research Funding; Genentech: Honoraria, Research Funding; Ascentage: Research Funding. Kadia:Jazz: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bioline RX: Research Funding; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Genentech: Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy, Research Funding. Takahashi:Symbio Pharmaceuticals: Consultancy. Jabbour:Takeda: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Adaptive: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Cyclacel LTD: Research Funding. Garcia-Manero:Helsinn: Research Funding; Novartis: Research Funding; AbbVie: Research Funding; Celgene: Consultancy, Research Funding; Astex: Consultancy, Research Funding; Onconova: Research Funding; H3 Biomedicine: Research Funding; Merck: Research Funding; Amphivena: Consultancy, Research Funding. Ravandi:Xencor: Consultancy, Research Funding; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Selvita: Research Funding; Cyclacel LTD: Research Funding; Macrogenix: Consultancy, Research Funding; Menarini Ricerche: Research Funding. Cortes:BMS: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Daiichi: Consultancy, Research Funding; Astellas: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Biopath: Consultancy; BiolineRx: Consultancy, Research Funding; Merus: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Jazz: Consultancy, Research Funding. Kantarjian:Pfizer: Honoraria, Research Funding; Immunogen: Research Funding; BMS: Research Funding; Cyclacel: Research Funding; Daiichi-Sankyo: Research Funding; Agios: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; Novartis: Research Funding; Ariad: Research Funding; Actinium: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria; Jazz Pharma: Research Funding; Amgen: Honoraria, Research Funding; Astex: Research Funding. DiNardo:celgene: Consultancy, Honoraria; daiichi sankyo: Honoraria; notable labs: Membership on an entity's Board of Directors or advisory committees; agios: Consultancy, Honoraria; syros: Honoraria; abbvie: Consultancy, Honoraria; medimmune: Honoraria; jazz: Honoraria." @default.
• W2985072863 created "2019-11-22" @default.
• W2985072863 creator A5000750846 @default.
• W2985072863 creator A5005883336 @default.
• W2985072863 creator A5010786159 @default.
• W2985072863 creator A5015101485 @default.
• W2985072863 creator A5016607292 @default.
• W2985072863 creator A5020340537 @default.
• W2985072863 creator A5022647201 @default.
• W2985072863 creator A5030500582 @default.
• W2985072863 creator A5049385583 @default.
• W2985072863 creator A5049467446 @default.
• W2985072863 creator A5050041791 @default.
• W2985072863 creator A5051949215 @default.
• W2985072863 creator A5061026876 @default.
• W2985072863 creator A5071658726 @default.
• W2985072863 creator A5074866197 @default.
• W2985072863 creator A5080350639 @default.
• W2985072863 creator A5083793750 @default.
• W2985072863 creator A5090435894 @default.
• W2985072863 date "2019-11-13" @default.
• W2985072863 modified "2023-10-15" @default.
• W2985072863 title "A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML" @default.
• W2985072863 doi "https://doi.org/10.1182/blood-2019-121780" @default.
• W2985072863 hasPublicationYear "2019" @default.
• W2985072863 type Work @default.
• W2985072863 sameAs 2985072863 @default.
• W2985072863 citedByCount "15" @default.
• W2985072863 countsByYear W29850728632020 @default.
• W2985072863 countsByYear W29850728632021 @default.
• W2985072863 countsByYear W29850728632023 @default.
• W2985072863 crossrefType "journal-article" @default.
• W2985072863 hasAuthorship W2985072863A5000750846 @default.
• W2985072863 hasAuthorship W2985072863A5005883336 @default.
• W2985072863 hasAuthorship W2985072863A5010786159 @default.
• W2985072863 hasAuthorship W2985072863A5015101485 @default.
• W2985072863 hasAuthorship W2985072863A5016607292 @default.
• W2985072863 hasAuthorship W2985072863A5020340537 @default.
• W2985072863 hasAuthorship W2985072863A5022647201 @default.
• W2985072863 hasAuthorship W2985072863A5030500582 @default.
• W2985072863 hasAuthorship W2985072863A5049385583 @default.
• W2985072863 hasAuthorship W2985072863A5049467446 @default.
• W2985072863 hasAuthorship W2985072863A5050041791 @default.
• W2985072863 hasAuthorship W2985072863A5051949215 @default.
• W2985072863 hasAuthorship W2985072863A5061026876 @default.
• W2985072863 hasAuthorship W2985072863A5071658726 @default.
• W2985072863 hasAuthorship W2985072863A5074866197 @default.
• W2985072863 hasAuthorship W2985072863A5080350639 @default.
• W2985072863 hasAuthorship W2985072863A5083793750 @default.
• W2985072863 hasAuthorship W2985072863A5090435894 @default.
• W2985072863 hasBestOaLocation W29850728631 @default.
• W2985072863 hasConcept C126322002 @default.
• W2985072863 hasConcept C136119220 @default.
• W2985072863 hasConcept C142424586 @default.
• W2985072863 hasConcept C143998085 @default.
• W2985072863 hasConcept C202444582 @default.
• W2985072863 hasConcept C2776694085 @default.
• W2985072863 hasConcept C2776730729 @default.
• W2985072863 hasConcept C2777938653 @default.
• W2985072863 hasConcept C2778461978 @default.
• W2985072863 hasConcept C2779675984 @default.
• W2985072863 hasConcept C2780775027 @default.
• W2985072863 hasConcept C33923547 @default.
• W2985072863 hasConcept C71924100 @default.
• W2985072863 hasConcept C86803240 @default.
• W2985072863 hasConcept C87355193 @default.
• W2985072863 hasConceptScore W2985072863C126322002 @default.
• W2985072863 hasConceptScore W2985072863C136119220 @default.
• W2985072863 hasConceptScore W2985072863C142424586 @default.
• W2985072863 hasConceptScore W2985072863C143998085 @default.
• W2985072863 hasConceptScore W2985072863C202444582 @default.
• W2985072863 hasConceptScore W2985072863C2776694085 @default.
• W2985072863 hasConceptScore W2985072863C2776730729 @default.
• W2985072863 hasConceptScore W2985072863C2777938653 @default.
• W2985072863 hasConceptScore W2985072863C2778461978 @default.
• W2985072863 hasConceptScore W2985072863C2779675984 @default.
• W2985072863 hasConceptScore W2985072863C2780775027 @default.
• W2985072863 hasConceptScore W2985072863C33923547 @default.
• W2985072863 hasConceptScore W2985072863C71924100 @default.
• W2985072863 hasConceptScore W2985072863C86803240 @default.
• W2985072863 hasConceptScore W2985072863C87355193 @default.
• W2985072863 hasIssue "Supplement_1" @default.
• W2985072863 hasLocation W29850728631 @default.
• W2985072863 hasOpenAccess W2985072863 @default.
• W2985072863 hasPrimaryLocation W29850728631 @default.
• W2985072863 hasRelatedWork W2351796763 @default.
• W2985072863 hasRelatedWork W2357191237 @default.
• W2985072863 hasRelatedWork W2567738959 @default.
• W2985072863 hasRelatedWork W2603651522 @default.
• W2985072863 hasRelatedWork W2766021132 @default.
• W2985072863 hasRelatedWork W2950208617 @default.
• W2985072863 hasRelatedWork W2985072863 @default.
• W2985072863 hasRelatedWork W3183236189 @default.
• W2985072863 hasRelatedWork W3216347831 @default.
• W2985072863 hasRelatedWork W87346260 @default.
• W2985072863 hasVolume "134" @default.
• W2985072863 isParatext "false" @default.
• W2985072863 isRetracted "false" @default.

• next